This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.70% per year. These returns cover a period from January 1, 1988 through April 6, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Analyst Blog: Archive
PLAB Q2 Earnings Miss on Delayed Semiconductor Design Releases
by Zacks Equity Research
Photronics' Q2 FY26 EPS and revenue miss estimates as IC revenues fall on delayed chip design releases; gross margin shrinks, and Q3 guidance remains cautious.
CIENNegative Net Change APHNegative Net Change MUPositive Net Change PLABNegative Net Change
earnings tech-stocks
OGS vs. NWN: Which Gas Utility Stock Is a Better Investment Pick?
by Zacks Equity Research
ONE Gas edges a regulated peer with bigger 2026 capex, lower debt-to-capital and faster EPS growth estimates.
NWNNegative Net Change OGSNegative Net Change
utilities
FUTU Q1 Earnings Fall Y/Y Due to RMB1.85B CSRC Penalty, Revenues Miss
by Zacks Equity Research
Futu's Q1 2026 revenues rise 24.7% but miss estimates, while net income sinks over 60% as an RMB1.85B proposed CSRC penalty hits results.
PRANegative Net Change AKRNegative Net Change ABCBNegative Net Change FUTUNegative Net Change
earnings finance tech-stocks
DLR Stock Rallies 19% in 6 Months: Will the Momentum Last?
by Zacks Equity Research
Digital Realty's cloud and AI-fueled demand, record bookings and $1.8B backlog boost growth prospects as it expands capacity worldwide.
AMTPositive Net Change LAMRNegative Net Change DLRNegative Net Change
reit
VIAV Stock Rises 430.7% in a Year: How to Play the Stock
by Aritra Chatterjee
VIAV surges 430.7% in a year as AI data center demand, aerospace growth and Spirent assets boost revenue outlook and testing market reach.
CIENNegative Net Change KEYSNegative Net Change VIAVNegative Net Change
communications tech-stocks
REPL Stock Soars on Plans of BLA Resubmission for Melanoma Combo Drug
by Zacks Equity Research
Replimune stock surges after the company aligned with the FDA on plans to resubmit its BLA for RP1 plus Opdivo in advanced melanoma.
BMYNegative Net Change REPLPositive Net Change LQDANegative Net Change IMCRPositive Net Change
biotechs
Merck's Calderasib Gets FDA's Breakthrough Therapy Tag for NSCLC
by Zacks Equity Research
MRK wins FDA Breakthrough Therapy designation for calderasib plus Keytruda for certain newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.
MRKNegative Net Change LQDANegative Net Change IMCRPositive Net Change
pharmaceuticals
MT Stock Hits 52-Week High: What's Driving Its Performance?
by Zacks Equity Research
ArcelorMittal hit a 52-week high after a Q1 earnings beat, backed by steel capacity expansion and shareholder returns.
MTPositive Net Change CRSPositive Net Change ALBNegative Net Change ASMNegative Net Change
basic-materials
UMB Financial Rises 18.3% in 6 Months: Should You Buy the Stock Now?
by Zacks Equity Research
UMBF stock gains 18.3% in six months, beating peers as Heartland deal, Fed cuts and fee income growth fuel stronger outlook.
HBANNegative Net Change UMBFNegative Net Change ASBNegative Net Change
finance
Should Investors Buy RYAAY Post a Four-Month Straight Traffic Growth?
by Zacks Equity Research
Ryanair lifts its fiscal 2027 traffic outlook to 216M passengers, signaling stronger demand and raising investor interest in the airline's momentum.
RYAAYNegative Net Change ALKNegative Net Change ALGTNegative Net Change
airlines transportation